Bli medlem
Bli medlem

Du är här


Xvivo Perfusion: XPST sold to a leading lung transplant clinic in Europe

The AKH University Hospital in Vienna, Austria, which is one of the
top three largest lung transplant clinics in Europe, has purchased an
XPS?. It is estimated that the installation of the XPS? will take
place at the beginning of June.

The clinic in Vienna has more than 30 years' experience of lung
transplantation and has a well-reputed lung transplant program for
being a leader in the field of Ex Vivo Lung Perfusion (EVLP). Austria
has the highest rate of lung transplants per million population
(13.3) according to the Global Observatory on Donation and
Transplantation. The Division of Thoracic Surgery in Vienna is a high
volume lung transplant center with more than 100 transplantations per

The AKH University Hospital has previously performed EVLP with the
manual method (without the XPS?) and for a period of time borrowed an
XPS?. According to the Company's business model, the pricing strategy
for capital goods, that is the EVLP machines LS? and XPS?, is so
designed that sales of capital goods do not have a significant
financial impact on the Company. According to the Company's pricing
strategy, future sales of STEEN Solution? for use in the EVLP
machines and accompanying single-use items are of financial
significance for the Company.

"The company are especially pleased that the AKH University Hospital
in Vienna has purchased an XPS? since the clinic in Vienna is in the
forefront of enlarging the use of donated lungs and has historically
performed ground breaking science in this area," says Magnus Nilsson,
CEO of XVIVO Perfusion.

May 19, 2020
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159,

Magnus Nilsson, CEO, +46 31 788 2150,

For further information on XVIVO Perfusion's business, please refer to
the company's website,

The information was submitted for publication, through the agency of
the contact person set out above, at 08:30 am CET on May 19, 2020.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in Lund, Sweden and one office in Denver, the USA. The XVIVO share is
listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More
information can be found on the website


XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:

Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.